GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CELLUMED Co Ltd (XKRX:049180) » Definitions » EV-to-EBITDA

CELLUMED Co (XKRX:049180) EV-to-EBITDA : -5.70 (As of Sep. 26, 2024)


View and export this data going back to 2002. Start your Free Trial

What is CELLUMED Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, CELLUMED Co's enterprise value is ₩156,670 Mil. CELLUMED Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was ₩-27,465 Mil. Therefore, CELLUMED Co's EV-to-EBITDA for today is -5.70.

The historical rank and industry rank for CELLUMED Co's EV-to-EBITDA or its related term are showing as below:

XKRX:049180' s EV-to-EBITDA Range Over the Past 10 Years
Min: -603.98   Med: -5.09   Max: 135.59
Current: -5.7

During the past 13 years, the highest EV-to-EBITDA of CELLUMED Co was 135.59. The lowest was -603.98. And the median was -5.09.

XKRX:049180's EV-to-EBITDA is ranked worse than
100% of 481 companies
in the Medical Devices & Instruments industry
Industry Median: 14.7 vs XKRX:049180: -5.70

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-09-26), CELLUMED Co's stock price is ₩3060.00. CELLUMED Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was ₩-700.000. Therefore, CELLUMED Co's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


CELLUMED Co EV-to-EBITDA Historical Data

The historical data trend for CELLUMED Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CELLUMED Co EV-to-EBITDA Chart

CELLUMED Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.87 62.86 21.15 -483.87 -2.95

CELLUMED Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.88 -9.22 -2.95 -2.83 -2.75

Competitive Comparison of CELLUMED Co's EV-to-EBITDA

For the Medical Instruments & Supplies subindustry, CELLUMED Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CELLUMED Co's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CELLUMED Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where CELLUMED Co's EV-to-EBITDA falls into.



CELLUMED Co EV-to-EBITDA Calculation

CELLUMED Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=156669.547/-27464.722
=-5.70

CELLUMED Co's current Enterprise Value is ₩156,670 Mil.
CELLUMED Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-27,465 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CELLUMED Co  (XKRX:049180) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

CELLUMED Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3060.00/-700.000
=At Loss

CELLUMED Co's share price for today is ₩3060.00.
CELLUMED Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-700.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


CELLUMED Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of CELLUMED Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


CELLUMED Co Business Description

Traded in Other Exchanges
N/A
Address
Acetechno Tower 9 402, Gasan-dong, Geumcheon-gu, Seoul, KOR, 153-782
CELLUMED Co Ltd is a Korean company which is engaged in manufacturing and sale of medical equipment and biosimilars. Its products portfolio includes allografts for tissue repair, bone sponges, bone powders and demineralized bone matrixes (DBMs) for bone regeneration and biosimilars such as bone morphogenetic protein 2 (BMP2) reagents and others. It also produces medical devices, such as spinal fixation systems, joint replacements, and navigation systems.

CELLUMED Co Headlines

No Headlines